1. Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
Lancet Neurol 2015;14:368-376.
2. Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
Lancet 2022;400:161-169.
3. Kvistad CE, Næss H, Helleberg BH, Idicula T, Hagberg G, Nordby LM, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, noninferiority trial.
Lancet Neurol 2022;21:511-519.
4. Wang Y, Li S, Pan Y, Li H, Parsons MW, Campbell BCV, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
Lancet 2023;401:645-654.
5. Muir K, Murray A, Wardlaw J, Ford I, Ford G. Abstract TMP24: alteplase-tenecteplase trial evaluation for stroke thrombolysis (ATTEST 2).
Stroke 2018;49(Suppl 1):ATMP24.
6. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.
N Engl J Med 2012;366:1099-1107.
7. Chandra A, Raina AF, Wani M, Ganie H, Dar W, Yaqoob A, et al. Efficacy outcomes of tenecteplase versus alteplase in patients with ischemic stroke in therapeutic window: experience from a single institution.
Arch Med Health Sci 2023;11:3-8.
8. George M, Baby N, Paul R, Zabeer M, Thomas C. Comparison of thrombolytic agents in treatment of patients with acute ischemic stroke; findings from a single centre follow up study in real-life settings.
J Clin Neurosci 2021;91:299-305.
9. Li S, Pan Y, Wang Z, Liang Z, Chen H, Wang D, et al. Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study.
Stroke Vasc Neurol 2022;7:47-53.
10. Warach SJ, Ranta A, Kim J, Song SS, Wallace A, Beharry J, et al. Symptomatic intracranial hemorrhage with tenecteplase vs alteplase in patients with acute ischemic stroke: the comparative effectiveness of routine tenecteplase vs alteplase in acute ischemic stroke (CERTAIN) collaboration.
JAMA Neurol 2023;80:732-738.
11. Saaiq M, Ashraf B. Modifying “pico” question into “picos” model for more robust and reproducible presentation of the methodology employed in a scientific study.
World J Plast Surg 2017;6:390-392.
13. Sterne JAC, Savovic´ J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials.
BMJ 2019;366:l4898.
14. Sterne JA, Hernán MA, Reeves BC, Savovic´ J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.
BMJ 2016;355:i4919.
15. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.
BMJ 2011;343:d4002.
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test.
BMJ 1997;315:629-634.
17. Balduzzi S, Rücker G, Schwarzer G. How to perform a metaanalysis with R: a practical tutorial.
Evid Based Ment Health 2019;22:153-160.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses.
BMJ 2003;327:557-560.
20. Fletcher J. What is heterogeneity and is it important?
BMJ 2007;334:94-96.
21. Tufanaru C, Munn Z, Stephenson M, Aromataris E. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness.
Int J Evid Based Healthc 2015;13:196-207.
22. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses.
BMJ 2011;342:d549.
23. Deeks JJ, Higgins JP, Altman DG; Cochrane Statistical Methods Group. Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. 2nd ed. Hoboken, NJ: Wiley, 2019;241-284.
24. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted?
Stat Med 2002;21:1559-1573.
25. Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression.
Stat Med 2004;23:1663-1682.
26. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.
BMJ 2008;336:924-926.
27. Bivard A, Zhao H, Churilov L, Campbell BCV, Coote S, Yassi N, et al. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne mobile stroke unit (TASTE-A): a phase 2, randomised, open-label trial.
Lancet Neurol 2022;21:520-527.
28. Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke.
N Engl J Med 2018;378:1573-1582.
29. Checkouri T, Gerschenfeld G, Seners P, Yger M, Ben Hassen W, Chausson N, et al. Early recanalization among patients undergoing bridging therapy with tenecteplase or alteplase.
Stroke 2023;54:2491-2499.
30. Dhar N, Kumar M, Tiwari A, Desai I, Madhaw G, Kumar N. Tenecteplase and alteplase for thrombolysis of acute ischemic stroke within 4.5 hours: an efficacy and safety study.
Ann Indian Acad Neurol 2022;25:897-901.
31. Estella Á, Pérez Ruiz M, Serrano JJ. Effectiveness and safety of tecneplase vs. alteplase in the acute treatment of ischemic stroke.
J Pers Med 2022;12:1525.
33. Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial.
Stroke 2010;41:707-711.
34. Hall J, Thon JM, Heslin M, Thau L, Yeager T, Siegal T, et al. Tenecteplase improves door-to-needle time in real-world acute stroke treatment.
Stroke Vasc Interv Neurol 2021;1:e000102.
35. Hendrix P, Collins MK, Griessenauer CJ, Goren O, Melamed I, Weiner GM, et al. Tenecteplase versus alteplase before mechanical thrombectomy: experience from a US healthcare system undergoing a system-wide transition of primary thrombolytic.
J Neurointerv Surg 2023;15:e277-e281.
36. Kuruttukulam G, Sundar K, Bhirud L, Panwar A, Alapatt PJ. Does tenecteplase before mechanical thrombectomy result in a faster revascularization as compared to alteplase? Observations from a comprehensive stroke care center in Southern India.
J Stroke Med 2023;6:40-45.
37. Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, Rønning OM, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
Lancet Neurol 2017;16:781-788.
38. Mahawish K, Gommans J, Kleinig T, Lallu B, Tyson A, Ranta A. Switching to tenecteplase for stroke thrombolysis: real-world experience and outcomes in a regional stroke network.
Stroke 2021;52:e590-e593.
39. Mohan A, Komakula S, Murali S, Anand P, Shah D, Vishnu VY, et al. Biosimilar tenecteplase versus alteplase in acute ischemic stroke: a real world study.
Ann Indian Acad Neurol 2023;26:54-58.
40. Murphy LR, Hill TP, Paul K, Talbott M, Golovko G, Shaltoni H, et al. Tenecteplase versus alteplase for acute stroke: mortality and bleeding complications.
Ann Emerg Med 2023;82:720-728.
41. Parsons MW, Miteff F, Bateman GA, Spratt N, Loiselle A, Attia J, et al. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window.
Neurology 2009;72:915-921.
43. Qureshi AI, Baskett WI, Bains NK, French BR, Siddiq F, Gomez CR, et al. Outcomes with IV tenecteplase and IV alteplase for acute ischemic stroke with or without thrombectomy in real-world settings in the United States.
J Stroke Cerebrovasc Dis 2023;32:106898.
44. Sjögren V, Ekici R, Faergemann E, Björck F. Feasibility of switching from alteplase to tenecteplase for stroke thrombolysis-a retrospective cohort analysis.
IBRO Neurosci Rep 2023;14:353-357.
45. Sundar K, Bhirud L, Panwar A, Cherian JJ, Paul EM, Kuruttukulam GV. Tenecteplase versus alteplase (TENVALT): a study comparing two thrombolytic agents in acute ischemic stroke. Neurol Asia 2019;24:203-208.
46. Teivane A, Jurja¯ns K, Ve¯tra J, Grigorjeva J, Kupcs K, Masiliu¯nas R, et al. Tenecteplase or alteplase better in patients with acute ischemic stroke due to large vessel occlusion: a single center observational study.
Medicina (Kaunas) 2022;58:1169.
47. Tsivgoulis G, Katsanos AH, Christogiannis C, Faouzi B, Mavridis D, Dixit AK, et al. Intravenous thrombolysis with tenecteplase for the treatment of acute ischemic stroke.
Ann Neurol 2022;92:349-357.
48. Walton MN, Hamilton LA, Salyer S, Wiseman BF, Forster AM, Rowe AS. Major bleeding postadministration of tenecteplase versus alteplase in acute ischemic stroke.
Ann Pharmacother 2023;57:535-543.
49. Warach SJ, Dula AN, Milling TJ, Miller S, Allen L, Zuck ND, et al. Prospective observational cohort study of tenecteplase versus alteplase in routine clinical practice.
Stroke 2022;53:3583-3593.
50. Zhao ZA, Qiu J, Wang L, Zhao YG, Sun XH, Li W, et al. Intraarterial tenecteplase is safe and may improve the first-pass recanalization for acute ischemic stroke with large-artery atherosclerosis: the BRETIS-TNK trial.
Front Neurol 2023;14:1155269.
51. Zhong CS, Beharry J, Salazar D, Smith K, Withington S, Campbell BCV, et al. Routine use of tenecteplase for thrombolysis in acute ischemic stroke.
Stroke 2021;52:1087-1090.
52. McHugh ML. Interrater reliability: the kappa statistic.
Biochem Med (Zagreb) 2012;22:276-282.
53. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II).
Lancet 1998;352:1245-1251.
54. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study.
Lancet 2007;369:275-282.
55. Tsai CF, Anderson N, Thomas B, Sudlow CL. Risk factors for ischemic stroke and its subtypes in Chinese vs. Caucasians: systematic review and meta-analysis.
Int J Stroke 2015;10:485-493.
56. Katsanos AH, Psychogios K, Turc G, Sacco S, de Sousa DA, De Marchis GM, et al. Off-label use of tenecteplase for the treatment of acute ischemic stroke: a systematic review and meta-analysis.
JAMA Netw Open 2022;5:e224506.
57. Rose D, Cavalier A, Kam W, Cantrell S, Lusk J, Schrag M, et al. Complications of intravenous tenecteplase versus alteplase for the treatment of acute ischemic stroke: a systematic review and meta-analysis.
Stroke 2023;54:1192-1204.
58. Katsanos AH, Safouris A, Sarraj A, Magoufis G, Leker RR, Khatri P, et al. Intravenous thrombolysis with tenecteplase in patients with large vessel occlusions: systematic review and metaanalysis.
Stroke 2021;52:308-312.